Anders Pedersen
Chief Operating Officer bij GALECTO, INC.
Vermogen: 2 697 $ op 29-02-2024
Profiel
Founder of Profound Pharma AS, Anders H.
Pedersen currently is Chief Operating Officer for Galecto, Inc. and Chief Operating Officer at Galecto Biotech ApS (a subsidiary of Galecto, Inc.).
In the past he occupied the position of Chief Operating Officer of Recepticon ApS, Manager-Projects & Department at Novo Nordisk A, Manager-Project & Department at Biotech, Vice President-Portfolio Management at Life Cycle Pharma A, Vice President-Research & Development of Profound Pharma AS, Senior Vice President-Development at AGC Biologics An and Principal at The University of New Mexico.
Anders H.
Pedersen received an undergraduate degree from Technical University of Denmark.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
GALECTO, INC.
0.01% | 04-01-2023 | 3 746 ( 0.01% ) | 2 697 $ | 29-02-2024 |
Actieve functies van Anders Pedersen
Bedrijven | Functie | Begin |
---|---|---|
GALECTO, INC. | Chief Operating Officer | 01-01-2020 |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Chief Operating Officer | 01-01-2013 |
Eerdere bekende functies van Anders Pedersen
Bedrijven | Functie | Einde |
---|---|---|
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Corporate Officer/Principal | 01-03-2013 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Chief Operating Officer | 01-11-2009 |
Life Cycle Pharma A/S | Corporate Officer/Principal | 01-11-2006 |
The University of New Mexico | Corporate Officer/Principal | 01-01-1990 |
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Founder | - |
Opleiding van Anders Pedersen
Technical University of Denmark | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
GALECTO, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Health Technology |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Health Technology |
Biotech
Biotech BiotechnologyHealth Technology The private company manufactures biotechnical products. The company is based in Cambridge, MA. | Health Technology |
Life Cycle Pharma A/S | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |